Here, we cluster lipid transcriptomic profiles and correlate them with immune and nonimmune cell enrichment signatures in a large cohort of AD transcriptomes from the brain and peripheral blood. Our analysis highlights the correlation between the dysregulation of lipid metabolism, immune activity, and cellular pathophysiology, thus providing druggable targets and a diagnostic tool. AD individuals have distinct lipid metabolism gene expression patterns and cell type correlations. Most clustered genes are enriched for immunocytes, providing insights into the dysregulation of lipid metabolism that affects the immune microenvironment.
Previous GWAS have suggested genetic correlations with AD and APOE, NPC1, and LAMTOR5, which are linked to disruptions in lipid transport and endosomal/lysosomal irregularities, implying that lipid metabolism signaling pathways underlie vulnerability to AD neurodegeneration(Giri et al. 2016). In our bioinformatic enrichment analysis, 21 unique genes in the AD hippocampus are involved in lipid metabolism processes, including fatty acid synthesis and elongation, phospholipid hydrolysis, and choline transmembrane transport. Dysregulation of PLD3(Hinz and Geschwind 2017), NDUFAB1(Wu et al. 2023), OXCT1(Zhang et al. 2020), PI4KA(Koran et al. 2014), and AACS(Perkins et al. 2016) has been observed in AD patients, and reduced transcription of these genes have been found at later stages of the disease (Braak IV/VI). However, six of 21 genes were upregulated in the AD hippocampus, including ELOVL6 and SLC44A1, which were not previously reported. Analyzing subpopulation expression has shown that SLC44A1 is expressed explicitly in oligodendrocytes; in contrast, AGT and ACSS3 are expressed exclusively in astrocytes, suggesting that dysregulation of lipid metabolism gene expression occurs heterogeneously involving several cell types.
Analysis of AD peripheral blood identified genes related to energy metabolism and nucleic acid processing that correlated with various neurodegenerative diseases. GSEA revealed nine hub lipid metabolism genes linked to neurodegenerative diseases, particularly AD, which validates this analysis. Three of the nine genes (DBI, RXRA, and MBOAT7) may be useful in clinical diagnostics. DBI(Mills et al. 2013) and RXRA(Kölsch et al. 2009) encode proteins that function in steroidogenesis and cholesterol metabolism in AD, respectively. MBOAT7 encodes the lysophosphatidylinositol acyltransferase that transfers arachidonic acid to lysophosphatidylinositol to produce phosphatidylinositol. Mutations in MBOAT7 lead to intellectual disability with epilepsy and autistic features(Johansen et al. 2016). We initially linked MBOAT7 to AD as a peripheral diagnostic marker, but we later identified CEBPB as a discriminant between MCI and AD that distinguishes the prodromal and clinical stages.
Neuroinflammation characterizes AD with the activation of immune cells and infiltration of activated peripheral immune cells into the CNS during AD progression. The immune infiltration mediated by naive B cells, endothelial cells, activated/resting NK cells, macrophages, CD4+ T cells, memory B cells, and dendritic cells participates in AD development (Gu et al. 2022, McLarnon 2021, Tian et al. 2022, Zlokovic 2011). An essential strength of this study is the exploration of lipid metabolism in inflammation and neuroinflammation. It has been found that distinct distributions and expression profiles between neurons and glial cells, innate immunocytes (e.g., mast cells and monocytes), and adaptive immunocytes (e.g., CD4+ T, CD8+ T) in the unsupervised clusters derived from brain and peripheral blood. In AD progression, immune T cells, such as CD8+ T cells, penetrate the brain parenchyma and bind tightly with neurons and microglia(Jorfi et al. 2023, Unger et al. 2020), as demonstrated by functional transcriptomic analysis of CD8+ T cells, which reveals distinctive activation profiles that are functionally involved in AD (Altendorfer et al. 2022). The lipid metabolism genes NDUFAB1, OXCT1, PI4K4, and ELOVL4 were significantly elevated in monocytes but reduced in T cells and NK cells. Although the molecular mechanisms remain incompletely understood, the transcriptional differences in lipid metabolism between the brains and blood cells of AD patients may link the varying contributions of these cells to AD pathology.
Although experimental evidence indicates eosinophil infiltration in amyloid plaque phagocytes, eosinophil can damage myelinated nerve fibers through secreted neurotoxin(Durack et al. 1979), and defects the recruitment of peripheral neutrophils (Fiala et al. 2005) even in early AD. Neutrophils promote disease pathology and cognitive decline in mouse models and AD patients, and depletion or inhibition of neutrophils restores the neuropathology(Gabbita et al. 2015, Zenaro et al. 2015). Conditional deletion of fatty acid synthase results in selective inhibition of neutrophil production, although without disrupting neutrophil differentiation. Consistent with previous reports(Järemo et al. 2013, Wu et al. 2020), we found elevated eosinophils and neutrophils in peripheral circulation in lipid genes clustering subtypes, which may indicate lipid metabolism functional involvement in systemic innate immune response in AD.
Unexpectedly, within the complete blood sample from GSE177477, two pathways were poorly expressed in COVID-19 and opposition to AD. COVID-19 patients exhibit neurological symptoms, including stroke, loss of taste and smell, and cognitive alterations. Transcriptomic analysis of COVID-19 victims revealed marked microglial activation(Fullard et al. 2021) and a significant influx of activated CD8+ T cells into the brain parenchyma (Yang et al. 2021). Single-cell sequencing of cerebrospinal fluid from patients with persistent COVID-19 infection revealed changes in CD4+ T-cell depletion. The COVID-19 pandemic profoundly impacted dementia patients, with more than two new symptoms occurring (Heming et al. 2021). Cellular lipid synthesis is needed for COVID-19 virus replication(Arthur et al. 2022), and pharmacologic inhibition of FAS blocks COVID-19 replication(Chu et al. 2021).
Treatment strategies based on the amyloid cascade hypothesis have proven ineffective, so identifying and exploring novel therapeutic targets is crucial to improving treatment. We used targeted drug prediction on DEGs within the DrugBank database to identify specific drugs that target central and peripheral protein products of these genes. Several medications target lipid metabolism for both immune and degenerative diseases. Sparsentan (DB12548) targets AGT in adults with primary immunoglobulin A nephropathy, which is characterized by rapid deterioration of galactose-deficient IgA1 antibodies; endothelin and angiotensin II receptor antagonists reduce proteinuria(Komers et al. 2020). By inhibiting IL-15 signaling mediated by angiotensin II or endothelin-1, sparsentan determines renal CD8+ TRM cell fate through a mechanistic pathway(Li et al. 2022). Zinc and copper perturbations have been observed in patients and AD models, which may indicate amyloidogenesis and tauopathy(Moynier et al. 2020, Solovyev et al. 2021). The substrates of SLC44A1, choline (DB00122), and choline salicylate (DB14006) are precursors of acetylcholine and are critical in lipid metabolism(Kolykhalov et al. 2022). Lipid transporter ALC44A2 inhibitors are promising candidates for treating immune and degenerative diseases(Traiffort et al. 2013).